CALGARY, June 4 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that Andrew Baum, president & CEO of the company, will present a corporate update at the Needham & Company, LLC Seventh Annual Biotechnology and Medical Technology Conference. The presentation is scheduled on Wednesday, June 11 at 2:30 p.m., at the New York Palace Hotel.
Interested parties may access a live webcast of the presentation by visiting the company’s website at www.sembiosys.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An audio archive of the presentation will be available for approximately 30 days.
About SemBioSys Genetics Inc.
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company’s lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys’ subsidiary, Botaneco, develops and supplies proprietary specialty ingredients to the personal care industry. More information is available at www.sembiosys.com.
CONTACT: SemBioSys Genetics Inc., Andrew Baum, President and Chief
Executive Officer, Phone: (403) 717-8767, E-mail: bauma@sembiosys.com; The
Trout Group, Ian Clements, Senior Vice President, Phone: (415) 392 3385,
E-mail: iclements@troutgroup.com
